Effects of ticagrelor monotherapy vs. clopidogrel monotherapy on platelet reactivity: a randomized, crossover clinical study (SINGLE study)

References

• Park DW, Kwon O, Jang JS, Yun S-C, Park H, Kang D-Y, Ahn J-M, Lee PH, Lee S-W, Park S-W, et al. Clinically significant bleeding with ticagrelor versus clopidogrel in korean patients with acute coronary syndromes intended for invasive management: a randomized clinical trial. Circulation 2019;140(23):1865–1877. doi:10.1161/CIRCULATIONAHA.119.041766
   PubMed Web of Science ®Google Scholar
• Becker RC, Bassand JP, Budaj A, Wojdyla DM, James SK, Cornel JH, French J, Held C, Horrow J, Husted S, et al. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial. Eur Heart J 2011;32(23):2933–2944. doi:10.1093/eurheartj/ehr422
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Badimon J. Overview of aspirin and platelet biology. Am J Cardiol 2021;144(Suppl 1):S2–S9. doi:10.1016/j.amjcard.2020.12.018
   PubMedGoogle Scholar
• Mehran R, Baber U, Sharma SK, Cohen DJ, Angiolillo DJ, Briguori C, Cha JY, Collier T, Dangas G, Dudek D, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381(21):2032–2042. doi:10.1056/NEJMoa1908419
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Badimon J. Duration of antiplatelet therapy after complex PCI in the TWILIGHT-COMPLEX trial: the Goldilocks dilemma. Cardiovasc Res 2020;116(8):e93–e95. doi:10.1093/cvr/cvaa135
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA 2019;321(24):2414–2427. doi:10.1001/jama.2019.8145
   PubMed Web of Science ®Google Scholar
• Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im E-S, Jeong J-O, Cho BR, Oh SK, et al. Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial. JAMA 2019;321(24):2428–2437. doi:10.1001/jama.2019.8146
   PubMed Web of Science ®Google Scholar
• Le Blanc J, Mullier F, Vayne C, Lordkipanidzé M. Advances in platelet function testing-light transmission aggregometry and beyond. J Clin Med 2020;9(8):2636. doi:10.3390/jcm9082636
   Web of Science ®Google Scholar
• Hobson AR, Agarwala RA, Swallow RA, Dawkins KD, Curzen NP. Thrombelastography: current clinical applications and its potential role in interventional cardiology. Platelets 2006;17(8):509–518. doi:10.1080/09537100600935259
   PubMed Web of Science ®Google Scholar
• Liu GZ, Zhang S, Sun DH, Shi J, Bo WL, Wang WN, Zhang CY, Wang ZH, Feng W, He MJ, et al. Half-dose ticagrelor versus high-dose clopidogrel in reducing platelet reactivity in acute coronary syndrome patients with high on-clopidogrel platelet reactivity (divide study). Eur J Clin Pharmacol 2019;75(8):1059–1068. doi:10.1007/s00228-019-02687-0
   PubMed Web of Science ®Google Scholar
• Tang YD, Wang W, Yang M, Zhang K, Chen J, Qiao S, Yan H, Wu Y, Huang X, Xu B, et al. Randomized comparisons of double-dose clopidogrel or adjunctive cilostazol versus standard dual antiplatelet in patients with high posttreatment platelet reactivity: results of the CREATIVE trial. Circulation 2018;137(21):2231–2245. doi:10.1161/CIRCULATIONAHA.117.030190
   PubMed Web of Science ®Google Scholar
• Zhang JH, Tang XF, Zhang Y, Wang J, Yao Y, Ma Y-L, Xu B, Gao R-L, Gao Z, Chen J, et al. Relationship between ABCB1 polymorphisms, thromboelastography and risk of bleeding events in clopidogrel-treated patients with ST-elevation myocardial infarction. Thromb Res 2014;134(5):970–975. doi:10.1016/j.thromres.2014.08.017
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: a new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010;160(2):346–354. doi:10.1016/j.ahj.2010.05.034
   PubMed Web of Science ®Google Scholar
• Harrison P, Frelinger AL 3rd, Furman MI, Michelson AD. Measuring antiplatelet drug effects in the laboratory. Thromb Res 2007;120(3):323–336. doi:10.1016/j.thromres.2006.11.012
   PubMed Web of Science ®Google Scholar
• Ling LQ, Liao J, Niu Q, Wang X, Jia J, Zuo C-H, Jiang H, Zhou J. Evaluation of an automated light transmission aggregometry. Platelets 2017;28(7):712–719. doi:10.1080/09537104.2016.1265923
   PubMed Web of Science ®Google Scholar
• Khanna V, Hobson A, Mikael R, Sambu N, Englyst N, Curzen N. Does the VerifyNow P2Y12 assay overestimate “therapeutic response” to clopidogrel? Insights using short thrombelastography. Thromb Haemost 2014;111(6):1150–1159. doi:10.1160/TH13-10-0856
   PubMed Web of Science ®Google Scholar
• Yang Y, Chen W, Pan Y, Yan H, Meng X, Liu L, Wang Y, Wang Y. Effect of ticagrelor versus clopidogrel on platelet reactivity measured by thrombelastography in patients with minor stroke or TIA. Aging (Albany NY) 2020;12(20):20085–20094. doi:10.18632/aging.103452
   PubMedGoogle Scholar
• Baber U, Zafar MU, Dangas G, Escolar G, Angiolillo DJ, Sharma SK, Kini AS, Sartori S, Joyce L, Vogel B, et al. Ticagrelor with or without aspirin after PCI: the TWILIGHT platelet substudy. J Am Coll Cardiol 2020;75(6):578–586. doi:10.1016/j.jacc.2019.11.056
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Leadbeater PD, Chan MV, Kirkby NS, Jakubowski JA, Mitchell JA, Warner TD. In the presence of strong P2Y12 receptor blockade, aspirin provides little additional inhibition of platelet aggregation. J Thromb Haemost 2011;9(3):552–561. doi:10.1111/j.1538-7836.2010.04160.x
   PubMed Web of Science ®Google Scholar
• Armstrong PC, Dhanji AR, Truss NJ, Zain ZNM, Tucker AT, Mitchell JA, Warner TD. Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness. Thromb Haemost 2009;102(4):772–778. doi:10.1160/TH09-04-0215
   PubMed Web of Science ®Google Scholar
• Guidetti GF, Lova P, Bernardi B, Campus F, Baldanzi G, Graziani A, Balduini C, Torti M. The Gi-coupled P2Y12 receptor regulates diacylglycerol-mediated signaling in human platelets. J Biol Chem 2008;283(43):28795–28805. doi:10.1074/jbc.M801588200
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Lecchi A. Inhibition of the platelet P2Y12 receptor for adenosine diphosphate potentiates the antiplatelet effect of prostacyclin. J Thromb Haemost 2007;5(3):577–582. doi:10.1111/j.1538-7836.2007.02356.x
   PubMed Web of Science ®Google Scholar
• Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, et al. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv 2019;12(4):e007811. doi:10.1161/CIRCINTERVENTIONS.119.007811
   PubMed Web of Science ®Google Scholar
• Waksman R, Maya J, Angiolillo DJ, Carlson GF, Teng R, Caplan RJ, Ferdinand, KC. Ticagrelor versus clopidogrel in black patients with stable coronary artery disease: prospective, randomized, open-label, multiple-dose, crossover pilot study. Circ Cardiovasc Interv 2015;8(7):e002232. doi:10.1161/CIRCINTERVENTIONS.114.002232
   PubMed Web of Science ®Google Scholar
• Bonello L, Laine M, Kipson N, Mancini J, Helal O, Fromonot J, Gariboldi V, Condo J, Thuny F, Frere C, et al. Ticagrelor increases adenosine plasma concentration in patients with an acute coronary syndrome. J Am Coll Cardiol 2014;63(9):872–877. doi:10.1016/j.jacc.2013.09.067
   PubMed Web of Science ®Google Scholar
• Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H, Husted S, Katus H, Keltai M, Khurmi NS, et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomized double-blind study. The Lancet 2010;375(9711):283–293. doi:10.1016/S0140-6736(09)62191-7
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher LA, Granger CB, Lange RA, Mack MJ, Mauri L, et al. ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. J Am Coll Cardiol 2016;68(10):1082–1115. doi:10.1016/j.jacc.2016.03.513
   PubMed Web of Science ®Google Scholar
• Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2018;39(3):213–260. doi:10.1093/eurheartj/ehx419
   PubMed Web of Science ®Google Scholar
• He MJ, Liu B, Sun DH, Pan Y, Zheng W, Shi J, Zhao S, Dong X, Lu S, Li M, et al. One-quarter standard-dose ticagrelor better than standard-dose clopidogrel in Chinese patients with stable coronary artery disease: a randomized, single-blind, crossover clinical study. Int J Cardiol 2016;215:209–213. doi:10.1016/j.ijcard.2016.04.087
   PubMed Web of Science ®Google Scholar
• He M, Li D, Zhang Y, Sun D, Liu G, Pan Y, Shi J, Li Y, Yin S, Li Y, et al. Effects of different doses of ticagrelor on platelet aggregation and endothelial function in diabetic patients with stable coronary artery disease. Platelets 2019;30(6):752–761. doi:10.1080/09537104.2018.1513479
   PubMed Web of Science ®Google Scholar
• He M, Zhang Y, Yan W, Liu G, Sun D, Yuan Y, Shi J, Kong Y, Li Y. 60 mg dose ticagrelor provides stronger platelet inhibition than clopidogrel in Chinese patients with chronic coronary syndrome: a randomized, single-blind, crossover study. Thromb Res 2020;190:60–61. doi:10.1016/j.thromres.2020.03.014
   PubMed Web of Science ®Google Scholar
• Shi J, He M, Wang W, Liu G, Zhang H, Sun D, Li J, Mu H, Xu M, Zhao C, et al. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Platelets 2021;32(1):120–129. doi:10.1080/09537104.2020.1732328
   PubMed Web of Science ®Google Scholar
• Lindkvist M, Fernberg U, Ljungberg LU, Fälker K, Fernström M, Hurtig-Wennlöf A, Grenegård M. Individual variations in platelet reactivity towards ADP, epinephrine, collagen and nitric oxide, and the association to arterial function in young, healthy adults. Thromb Res 2019;174:5–12. doi:10.1016/j.thromres.2018.12.008
   PubMed Web of Science ®Google Scholar
• Wallace MA, Agarwal KC, Garcia-Sainz JA, Fain JN. Alpha-adrenergic stimulation of phosphatidylinositol synthesis in human platelets as an alpha-2 effect secondary to platelet aggregation. J Cell Biochem 1982;18(2):213–220. doi:10.1002/jcb.1982.240180208
   PubMed Web of Science ®Google Scholar
• Storey RF, Bliden KP, Patil SB, Karunakaran A, Ecob R, Butler K, Teng R, Wei C, Tantry US, Gurbel PA, et al. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol 2010;56(3):185–193. doi:10.1016/j.jacc.2010.01.062
   PubMed Web of Science ®Google Scholar